Tango Therapeutics Inc

-0.05 (-0.67%)
1:08:39 PM EDT: $7.45 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)652.52M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.32 Million
Adjusted EPS-$0.36
See more estimates
10-Day MA$7.66
50-Day MA$6.00
200-Day MA$6.04
See more pivots

Tango Therapeutics Inc Stock, NASDAQ:TNGX

100 Binney Street, Unit 700, Cambridge, Massachusetts 02142
United States of America
Phone: +1.857.320.4900
Number of Employees: 91


Tango Therapeutics, Inc. operates as a biotechnology company, which engages in discovering and delivering precision cancer medicines. Its primary program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.